The invention relates to vascular repair devices, and, in particular, intravascular stents for repairing bifurcations, blood vessels that are diseased. Stents are particularly useful in the treatment of atherosclerotic stenosis in arteries and blood vessels. More particularly, the invention concerns improved stent patterns for a portal region on a side branch access stent to prevent the occurrence of portal overlap during deployment of the stent. The invention further provides a method of making a stent for repairing a bifurcated vessel.
Stents conventionally repair blood vessels that are diseased. Stents are generally hollow and cylindrical in shape and have terminal ends that are generally perpendicular to their longitudinal axis. In use, the conventional stent is positioned at the diseased area of a vessel and, after deployment, the stent provides an unobstructed pathway for blood flow.
Repair of vessels that are diseased at a bifurcation is particularly challenging since the stent must be precisely positioned, provide adequate coverage of the diseased area, provide access to any diseased area located distal to the bifurcation, and maintain vessel patency in order to allow adequate blood flow to reach the myocardium. Therefore, the stent must provide adequate coverage to the diseased portion of the bifurcated vessel, without compromising blood flow, and extend to a point within and beyond the diseased portion. Where the stent provides coverage to the vessel at the diseased portion, yet extends into the vessel lumen at the bifurcation, the diseased area is repaired, but blood flow may be compromised in other portions of the bifurcation. Unapposed stent elements may promote lumen compromise during neointimal formation and healing, producing restenosis and requiring further procedures. Moreover, by extending into the vessel lumen at the bifurcation, the stent may block access to further interventional procedures.
Conventional stents are designed to repair areas of blood vessels that are removed from bifurcations, and, therefore are associated with a variety of problems when attempting to use them to treat lesions at a bifurcation. Conventional stents are normally deployed so that the entire stent is either in the parent vessel or the proximal portion of the stent is in the parent vessel and the distal portion is located in the side branch vessel. In both cases, either the side branch vessel (former case) or the parent vessel (later case), would become “jailed” by the stent struts. This technique repairs one vessel at the bifurcation at the expense of jailing or obstructing the alternate vessel. Blood flow into the jailed vessel would be compromised as well as future access and treatment into the distal portion of the jailed vessel.
Alternatively, access into a jailed vessel can be attained by carefully placing a guide wire through the stent, and subsequently tracking a balloon catheter through the stent struts. The balloon could then be expanded, thereby deforming the stent struts and forming an opening into the previously jailed vessel. The cell to be spread apart must be randomly and blindly selected by recrossing the deployed stent with a guide wire. The drawback with this approach is that there is no way to determine or guarantee that the main vessel stent struts are properly oriented with respect to the side branch or that an appropriate stent cell has been selected by the wire for dilatation. The aperture created often does not provide a clear opening and creates a major distortion in the surrounding stent struts. A further drawback with this approach is that there is no way to tell if the main vessel stent struts have been properly oriented and spread apart to provide a clear opening for stenting the side branch vessel. This technique also causes stent deformation to occur in the area adjacent to the carina, pulling the stent away from the vessel wall and partially obstructing flow in the originally non jailed vessel. Deforming the stent struts to regain access into the previously jailed strut is also a complicated and time consuming procedure associated with attendant risks to the patient and is typically performed only if considered an absolute necessity. Vessels which supply a considerable amount of blood supply to the myocardium and may be responsible for the onset of angina or a myocardial infarction would necessitate the subsequent strut deformation in order to reestablish blood flow into the vessel. The risks of procedural complications during this subsequent deformation are considerably higher than stenting in normal vessels. The inability to place a guide wire through the jailed lumen in a timely fashion could restrict blood supply and begin to precipitate symptoms of angina or even cardiac arrest. In addition, platelet agitation and subsequent thrombus formation at the jailed site could further compromise blood flow into the side branch.
Plaque shift is also a phenomenon which is of concern when deploying a stent across a bifurcation. Plaque shift occurs when treatment of disease or plaque in one vessel causes the plaque to shift into another location. This is of greatest concern when the plaque is located on the carina or the apex of the bifurcation. During treatment of the disease the plaque may shift from one side of the carina to the other thereby shifting the obstruction from one vessel to the alternate vessel.
In another prior art method of implanting stents, a “T” stent procedure includes implanting a stent in the side branch ostium of the bifurcation followed by stenting the main vessel across the side branch and subsequently deforming the struts as previously described, to allow blood flow and access into the side branch vessel. Alternatively, a stent is deployed in the parent vessel and across the side branch origin followed by subsequent strut deformation as previously described, and finally a stent is placed into the side branch vessel. T stenting may be necessary in some situations in order to provide further treatment and additional stenting in the side branch vessel. This is typically necessitated when the disease is concentrated at the origin of the jailed vessel. This procedure is also associated with the same issues and risks previously described when stenting only one vessel and deforming the struts through the jailed vessel. In addition, since a conventional stent generally terminates at right angles to its longitudinal axis, the use of conventional stents to treat the origin of the previously jailed vessel (typically the side branch vessel) may result in blocking blood flow of the originally non-jailed vessel (typically the parent vessel) or fail to provide adequate coverage of the disease in the previously jailed vessel (typically a side branch vessel). The conventional stent might be placed proximally in order to provide full coverage around the entire circumference of the side branch, however this leads to a portion of the stent extending into the pathway of blood flow of the parent vessel. The conventional stent might alternatively be placed distally to, but not entirely overlaying the circumference of the origin of the side branch to the diseased portion. Such a position of the conventional stent results in a bifurcation that does not provide full coverage or has a gap on the proximal side (the origin of the side branch) of the vessel and is thus not completely repaired. The only conceivable situation that the conventional stent, having right angled terminal ends, could be placed where the entire circumference of the ostium is repaired without compromising blood flow, is where the bifurcation is formed of right angles. In such scenarios, extremely precise positioning of the conventional stent is required. This extremely precise positioning of the conventional stent may result with the right angled terminal ends of the conventional stent overlying the entire circumference of the ostium to the diseased portion without extending into a side branch, thereby repairing the right angled bifurcation.
To circumvent or overcome the problems and limitations associated with conventional stents in the context of repairing diseased bifurcated vessels, a stent that consistently overlays most of the diseased area of the bifurcation and provides adequate access to distal disease without subjecting the patient to any undue risks may be employed. Such a stent would have the advantage of providing adequate coverage at the proximal edge of the origin of the side branch such that a conventional stent which terminates at right angles to its longitudinal axis can be deployed in the side branch or alternate vessel without leaving a significant gap at the origin of the side branch. In addition, such a stent would allow access to all portions of the bifurcated vessel should further interventional treatment be necessary.
In another prior art method for treating bifurcated vessels, commonly referred to as the “Culotte technique,” the side branch vessel is first stented so that the stent protrudes into the main or parent vessel. A dilatation is then performed in the main or parent vessel to open and stretch the stent struts extending across the lumen from the side branch vessel. Thereafter, a stent is implanted in the side branch so that its proximal end overlaps with the parent vessel. One of the drawbacks of this approach is that the orientation of the stent elements protruding from the side branch vessel into the main vessel is completely random. In addition excessive metal coverage exists from overlapping strut elements in the parent vessel proximal to the carina area. Furthermore, the deployed stent must be recrossed with a wire blindly and arbitrarily selecting a particular stent cell. When dilating the main vessel the stent struts are randomly stretched, thereby leaving the possibility of restricted access, incomplete lumen dilatation, and major stent distortion.
In another prior art procedure, known as “kissing” stents, a stent is implanted in the main vessel with a side branch stent partially extending into the main vessel creating a double barreled lumen of the two stents in the main vessel distal to the bifurcation. Another prior art approach includes a so called “trouser legs and seat” approach, which includes implanting three stents, one stent in the side branch vessel, a second stent in a distal portion of the main vessel, and a third stent, or a proximal stent, in the main vessel just proximal to the bifurcation.
All of the foregoing stent deployment assemblies suffer from the same problems and limitations. Typically, there are uncovered intimal surface segments on the main vessel and side branch vessels between the stented segments or there is excessive coverage in the parent vessel proximal to the bifurcation. An uncovered flap or fold in the intima or plaque will invite a “snowplow” effect, representing a substantial risk for subacute thrombosis, and the increased risk of the development of restenosis. Further, where portions of the stent are left unapposed within the lumen, the risk for subacute thrombosis or the development of restenosis again is increased. The prior art stents and delivery assemblies for treating bifurcations are difficult to use and deliver making successful placement nearly impossible. Even where placement has been successful, the side branch vessel can be “jailed” or covered so that there is impaired access to the stented area for subsequent intervention. Further, even with the various patterns of the portal region of a currently manufactured type of bifurcated stent, there is a tendency of the ring or rings of the portal region to immediately overlap with an adjacent ring of the proximal section during stent deployment. The present invention solves these and other problems as will be shown.
The present invention provides for improved stent patterns for the portal region of a side branch access stent to prevent the occurrence of portal overlap during deployment of the stent. A method of making a stent for repairing a bifurcated vessel is further disclosed herein.
The stent of the present invention includes a cylindrical body having a proximal opening, a distal opening, and a central (portal) opening. The distal opening and the proximal opening are aligned along the stent longitudinal axis and typically would be implanted in the main vessel, while the central opening is radially offset relative to the alignment of the distal opening and the proximal opening. The stent is implanted so that the central opening provides access to the side branch (or alternative vessel) and the ring or rings proximal to the central opening provide support and coverage to the origin of the side branch and to the area immediately proximal to the carina. The cylindrical body of the stent includes a plurality of rings aligned along a longitudinal axis, where each ring has a delivery diameter in which it is crimped or compressed tightly onto the balloon catheter, and an implanted diameter where the stent is implanted in a bifurcated vessel. Each ring also includes a number of first peaks that are configured to spread apart to permit the rings to be greatly expanded outwardly or to be compressed radially inwardly onto the balloon portion of a delivery catheter.
In one embodiment, the cylindrical body includes a proximal section, a distal section, and a central section. The proximal section includes between one and fifteen rings, the distal section includes between one and fifteen rings, and the central section includes between one and ten rings. The number of first peaks in the central section differs from the number of first peaks in the proximal section and the distal section. The plurality of first peaks have a proximal end and distal end such that the proximal end of at least one first peak of the central section is connected to the distal end of at least one first peak of the proximal section by at least one link. A central opening of the distal section is adjacent to the proximal end of the at least one first peak of the central section connected to the distal end of the at least one first peak of the proximal section by the at least one link.
In another embodiment, the rings of the proximal section have between four and twelve first peaks, the rings of the distal section have between four and twelve first peaks, and the rings of the central section have between five and fifteen first peaks. In another embodiment of the stent, the rings of the proximal section have seven first peaks, the rings of the distal section have six first peaks, and the rings of the central section have eight first peaks. In each of the embodiments, the rings are connected by at least one link between adjacent rings. The links connecting the rings can have various embodiments including straight segments, curved segments, undulating segments, and non-linear segments.
In yet another embodiment, the number of first peaks in the rings of the central section is proportional to the number of links connecting the first peaks of the central section and proximal section.
In a further embodiment, the central section includes one ring having eight first peaks such that the proximal end of one first peak of the central section is connected to the distal end of one first peak of the proximal section by two links. In another embodiment, the central section includes one ring having eight first peaks such that the proximal end of two first peaks of the central section is each connected to the distal end of one first peak of the proximal section and to the distal end of one second peak of the proximal section by one link.
In another embodiment, the proximal end of the at least one first peak of the central section and the distal end of the at least one first peak of the proximal section are connected in an out of phase configuration.
The plurality of first peaks of the stent of the present invention are formed of struts having a length. In one embodiment, the length of the first peaks is inversely proportional to the length of the at least one link connecting the first peaks of the central section and the proximal section of the stent.
Each ring of the stent of the present invention has at least one second peak where at least some of the at least one second peaks are connected to a link.
The stent of the present invention includes struts that make up the rings and links, the struts having either uniform cross-section, or cross-sections having various widths and thicknesses.
In another embodiment, the stent of the present invention is coated with at least one layer of a therapeutic agent or drug. In such instance, at least a portion of the stent can be coated with a primer material, which adheres to the stent, the primer material being coated with at least one layer of a therapeutic agent or drug.
The present invention also provides for a method of making a stent for repairing a bifurcated vessel.
Other features and advantages of the invention will become apparent from the following detailed description taken in conjunction with the accompanying drawings, which illustrate, by way of example, the features of the invention.
The present invention is directed to improved stent patterns for the portal region of a stent in the treatment of a bifurcation in the coronary arteries, veins, peripheral vessels, and other body lumens. Prior art attempts at implanting intravascular stents in a bifurcation have proved less than satisfactory. For example,
Referring to
In treating side branch vessel 5, if a prior art stent is used in which there is no acute angle at the proximal end of the stent to match the angle of the bifurcation, a condition as depicted in
The stent of the present invention can be implanted in the main or side branch vessels to treat a number of disease configurations at a bifurcation including, but not limited to, the following:
1. Treatment of a parent or main vessel and the origin of the side branch at a bifurcation with any angle associated between the side branch and parent vessel.
2. Treatment of a parent vessel proximal to the carina and the side branch vessel simultaneously.
3. Treatment of the proximal vessel extending only into the origin of the side branch and the origin of the distal parent at the bifurcation.
4. Treatment of the area at the bifurcation only.
5. The origin of an angulated posterior descending artery.
6. The origin of an LV extension branch just at and beyond the crux, sparing the posterior descending artery.
7. The origin of a diagonal from the left anterior descending.
8. The left anterior descending at, just proximal to, or just distal to the diagonal origin.
9. The origin of a marginal branch of the circumflex.
10. The circumflex at, just proximal to, or just distal to the marginal origin.
11. The origin of the left anterior descending from the left main.
12. The origin of the circumflex from the left main.
13. The left main at or just proximal to its bifurcation.
14. Any of many of the above locations in conjunction with involvement of the bifurcation and an alternate vessel.
15. Any bifurcated vessels within the body where conventional stenting would be considered a therapeutic means of treatment proximal or distal to the bifurcation.
The present invention stent is an improvement over an existing stent specifically designed for treating bifurcations, known as the Multi-Link Frontier™ Side Branch Access Coronary Stent (“Frontier™ stent”), manufactured by Advanced Cardiovascular Systems, Inc. of Santa Clara, Calif. Each of the prior art devices depicted in
The stent pattern of the present invention is novel in that it provides for vessel wall coverage of the main branch vessel and at least partial coverage of the origin of the side branch vessel. More specifically, in
The bifurcated stent 20 of the present invention may be referred to as a “trap door” stent since the central portion of the stent is somewhat hidden during delivery and opens like a trap door to treat a bifurcated vessel when the stent is expanded. The stent of the present invention has a cylindrical body 21 that includes a proximal end 22 and a distal end 23. The stent has an outer surface 24 which contacts the vascular wall when implanted and an inner surface 25 through which blood flows when the stent is expanded and implanted. The stent can be described as having numerous connected rings 30 aligned along a common longitudinal axis of the stent. The rings are formed of undulating portions which include first peaks 34 that are configured to be spread apart to permit the stent to be expanded to a larger diameter or compressed tightly toward each other to a smaller diameter onto a catheter. The rings are connected to each other by at least one link 31 between adjacent rings so that the rings are in an in phase configuration (rings point in the same direction). Typically, there are three links that connect adjacent rings and the links of one ring are circumferentially offset by about 60° from the links of an adjacent ring. While the links 31 typically are offset as indicated, this is not always the case, especially in the area of the trap door. The number of links between adjacent rings does vary, however, in view of the trap door configuration.
The cylindrical body of the stent has a proximal section 26, a distal section 29 and a central section 28 where the proximal section can have between one and fifteen rings 30, the distal section can have between one and fifteen rings, and the central section will have between one and ten rings. The number of first peaks 34 in the central section generally will differ from the number of first peaks 34 in the proximal section and the distal section.
The central section 28 is essentially the trap door portion of the stent and is enlarged to appose the entrance to the side branch vessel when the stent is expanded. As used herein, “appose” means that the expanded stent comes into contact with the vessel or artery wall. By way of example, in one embodiment shown in
A central opening 40 in the distal section 29 of the stent allows the passage of a balloon contained on the delivery system. The stent is to be crimped tightly onto two separate expandable members of a catheter. Typically, the expandable portions of the catheter will be balloons similar to a dilatation type balloon for conventional dilatation catheters. In the present invention, the bifurcated stent 20 is configured such that the stent has a distal opening 36 and a proximal opening 38 that are in axial alignment and through which a longer balloon extends, and the central opening 40 which is adjacent the central section 28 or “trap door,” through which a shorter balloon extends. The stent can be crimped tightly onto both the long and short balloons. In this embodiment, the central opening of the distal section is adjacent to the proximal end 42 of one first peak of the central section connected to the distal end 44 of one first peak of the proximal section by link 46.
In another embodiment shown in
It is contemplated by the present invention that the at least one link 46 connecting one first peak 34 of the central section 28 to an adjacent first peak 34 of the proximal section 26 can be of various shapes and sizes, including standard straight links 57, long straight links 58, and non-linear links 60 having curved portions. In one embodiment shown in
In a further embodiment shown in
With all of the embodiments of the bifurcated stent 20 disclosed herein, the rings 30 can be attached to each other by links 31 having various shapes, including straight links 32 or non linear links 33 having curved portions. The non linear links, as shown in
Each embodiment of the stent 20 also can have rings 30 and links 31 that have variable thickness struts 52A and 52B, as shown in
The bifurcated stent 20 can be formed in a conventional manner typically by laser cutting a tubular member or by laser cutting a pattern (as in one of the embodiments disclosed herein) into a flat sheet, rolling it into a cylindrical body, and laser welding a longitudinal seam along the longitudinal edges of the stent. The stent can also be fabricated using conventional lithographic and etching techniques where a mask is applied to a tube or flat sheet. The mask is in the shape of the final stent pattern and is used for the purpose of protecting the tubing during a chemical etching process which removes material from unwanted areas. Electro discharge machining (EDM) can also be used for fabricating the stent, where a mold is made in the negative shape of the stent and is used to remove unwanted material by use of an electric discharge. The method of making stents using laser cutting processes or the other described processes are well known in the art. The stent of the invention typically is made from a metal alloy and includes any of stainless steel, titanium, nickel titanium (NiTi or nitinol of the shape memory or superelastic types), tantalum, cobalt chromium, cobalt chromium vanadium, cobalt chromium tungsten, gold, silver, platinum, platinum iridium or any combination of the foregoing metals and metal alloys. Any of the listed metals and metal alloys can be coated with a polymer containing fluorine 19 (19F) used as a marker which is visible under magnetic resonance imaging (MRI). Portions of the stent, for example some of the links, can be formed of a polymer impregnated with 19F so that the stent is visible under MRI. Other compounds also are known in the art to be visible under MRI and can be used in combination with the disclosed metal stent of the invention.
The stent of the invention also can be coated with a drug or therapeutic agent to assist in repair of the bifurcated vessel and may be useful, for example, in reducing the likelihood of the development of restenosis. Further, it is well known that the stent (usually made from a metal) may require a primer material coating to provide a substrate on which a drug or therapeutic agent is coated since some drugs and therapeutic agents do not readily adhere to a metallic surface. The drug or therapeutic agent can be combined with a coating or other medium used for controlled release rates of the drug or therapeutic agent. Examples of therapeutic agents or drugs that are suitable for use in accordance with the present invention include 17-beta estradiol, sirolimus, everolimus, actinomycin D (ActD), taxol, paclitaxel, or derivatives and analogs thereof. Examples of agents include other antiproliferative substances as well as antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, and antioxidant substances. Examples of antineoplastics include taxol (paclitaxel and docetaxel). Further examples of therapeutic drugs or agents include antiplatelets, anticoagulants, antifibrins, antiinflammatories, antithrombins, and antiproliferatives. Examples of antiplatelets, anticoagulants, antifibrins, and antithrombins include, but are not limited to, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor (available from Biogen located in Cambridge, Mass.), and 7E-3B® (an antiplatelet drug from Centocor located in Malvern, Pa.). Examples of antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, and mutamycin. Examples of cytostatic or antiproliferative agents include angiopeptin (a somatostatin analog from Ibsen located in the United Kingdom), angiotensin converting enzyme inhibitors such as Captopril® (available from Squibb located in New York, N.Y.), Cilazapril® (available from Hoffman-LaRoche located in Basel, Switzerland), or Lisinopril® (available from Merck located in Whitehouse Station, N.J.); calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, Lovastatin® (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck), methotrexate, monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available from GlaxoSmithKline located in United Kingdom), Seramin (a PDGF antagonist), serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. Other therapeutic drugs or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, and dexamethasone.
While the foregoing therapeutic agents have been used to prevent or treat restenosis, they are provided by way of example and are not meant to be limiting, since other therapeutic drugs may be developed which are equally applicable for use with the present invention. The treatment of diseases using the above therapeutic agents is known in the art. The calculation of dosages, dosage rates and appropriate duration of treatment are previously known in the art. Furthermore, the therapeutic drugs or agents are loaded at desired concentration levels per methods well known in the art to render the device ready for implantation.
It should be understood that any reference in the specification or claims to a drug or therapeutic agent being coated on the stent is meant that one or more layers can be coated either directly on the stent or onto a primer material on the stent to which the drug or therapeutic agent readily attaches.
While particular forms of the invention have been illustrated and described, it will be apparent to those skilled in the art that various modifications can be made without departing from the scope of the invention. Accordingly, it is not intended that the invention be limited except as by the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
2978787 | Leibig | Apr 1961 | A |
2990605 | Densyk | Jul 1961 | A |
3029819 | Starks | Apr 1962 | A |
3096560 | Liebig | Jul 1963 | A |
3142067 | Liebig | Jul 1964 | A |
3657744 | Ersek | Apr 1972 | A |
3908662 | Razgulov et al. | Sep 1975 | A |
3945052 | Liebig | Mar 1976 | A |
4041931 | Elliott et al. | Aug 1977 | A |
4047252 | Liebig et al. | Sep 1977 | A |
4061134 | Samuels et al. | Dec 1977 | A |
4108161 | Samuels et al. | Aug 1978 | A |
4140126 | Choudhury | Feb 1979 | A |
4193137 | Heck | Mar 1980 | A |
4202349 | Jones | May 1980 | A |
4214587 | Sakura, Jr. | Jul 1980 | A |
4517687 | Liebig et al. | May 1985 | A |
4560374 | Hammerslag | Dec 1985 | A |
4562596 | Kornberg | Jan 1986 | A |
4577631 | Kreamer | Mar 1986 | A |
4617932 | Kornberg | Oct 1986 | A |
4652263 | Herweck et al. | Mar 1987 | A |
4693249 | Schenck et al. | Sep 1987 | A |
4728328 | Hughes et al. | Mar 1988 | A |
4732152 | Wallsten et al. | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4795458 | Regan | Jan 1989 | A |
4795465 | Marten | Jan 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4872874 | Taheri | Oct 1989 | A |
4878906 | Lendemann et al. | Nov 1989 | A |
4892539 | Koch | Jan 1990 | A |
4969890 | Sugita et al. | Nov 1990 | A |
4969896 | Shors | Nov 1990 | A |
4994071 | MacGregor | Feb 1991 | A |
5026377 | Burton et al. | Jun 1991 | A |
5047050 | Arpesani | Sep 1991 | A |
5104399 | Lazarus | Apr 1992 | A |
5108424 | Hoffman, Jr. et al. | Apr 1992 | A |
5127919 | Ibrahim et al. | Jul 1992 | A |
5156619 | Ehrenfeld | Oct 1992 | A |
5178630 | Schmitt | Jan 1993 | A |
5178634 | Ramos Martinez | Jan 1993 | A |
5197976 | Herweck et al. | Mar 1993 | A |
5197977 | Hoffman, Jr. et al. | Mar 1993 | A |
5304220 | Maginot | Apr 1994 | A |
5316023 | Palmaz et al. | May 1994 | A |
5360443 | Barone et al. | Nov 1994 | A |
5443497 | Venbrux | Aug 1995 | A |
5443498 | Fontaine | Aug 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5462530 | Jang | Oct 1995 | A |
5507769 | Marin et al. | Apr 1996 | A |
5522880 | Barone et al. | Jun 1996 | A |
5527355 | Ahn | Jun 1996 | A |
5562724 | Vorwerk et al. | Oct 1996 | A |
5562726 | Chuter | Oct 1996 | A |
D376011 | Nunokawa | Nov 1996 | S |
5571167 | Maginot | Nov 1996 | A |
5571170 | Palmaz et al. | Nov 1996 | A |
5571171 | Barone et al. | Nov 1996 | A |
5571173 | Parodi | Nov 1996 | A |
5575817 | Martin | Nov 1996 | A |
5578071 | Parodi | Nov 1996 | A |
5578072 | Barone et al. | Nov 1996 | A |
5591228 | Edoga | Jan 1997 | A |
5591229 | Parodi | Jan 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5613980 | Chauhan | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5632763 | Glastra | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5643340 | Nunokawa | Jul 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5676696 | Marcade | Oct 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683450 | Goicoechea et al. | Nov 1997 | A |
5683452 | Barone et al. | Nov 1997 | A |
5683453 | Palmaz | Nov 1997 | A |
5693084 | Chuter | Dec 1997 | A |
5693086 | Goicoechea et al. | Dec 1997 | A |
5693087 | Parodi | Dec 1997 | A |
5693088 | Lazarus | Dec 1997 | A |
5695517 | Marin et al. | Dec 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5709713 | Evans et al. | Jan 1998 | A |
5713917 | Leonhardt et al. | Feb 1998 | A |
5718724 | Goicoechea et al. | Feb 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5749825 | Fischell et al. | May 1998 | A |
5755734 | Richter et al. | May 1998 | A |
5755735 | Richter et al. | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5776180 | Goicoechea et al. | Jul 1998 | A |
5782906 | Marshall et al. | Jul 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5800520 | Fogarty et al. | Sep 1998 | A |
5827229 | Auth et al. | Oct 1998 | A |
5827320 | Richter et al. | Oct 1998 | A |
5893887 | Jayaraman | Apr 1999 | A |
5895407 | Jayaraman | Apr 1999 | A |
5916234 | Lam | Jun 1999 | A |
5916263 | Goicoechea et al. | Jun 1999 | A |
5919225 | Lau et al. | Jul 1999 | A |
5921995 | Kleshinski | Jul 1999 | A |
5925075 | Myers et al. | Jul 1999 | A |
5938696 | Goicoechea et al. | Aug 1999 | A |
5938697 | Killion et al. | Aug 1999 | A |
5954693 | Barry | Sep 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
5976155 | Foreman et al. | Nov 1999 | A |
6017363 | Hojeibane | Jan 2000 | A |
6030413 | Lazarus | Feb 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6030415 | Chuter | Feb 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6039754 | Caro | Mar 2000 | A |
6048361 | Von Oepen | Apr 2000 | A |
6051020 | Goicoechea et al. | Apr 2000 | A |
6059824 | Taheri | May 2000 | A |
6066167 | Lau et al. | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6090133 | Richter et al. | Jul 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099560 | Penn et al. | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6117117 | Mauch | Sep 2000 | A |
6129738 | Lashinski et al. | Oct 2000 | A |
6129754 | Kanesaka et al. | Oct 2000 | A |
6129756 | Kugler et al. | Oct 2000 | A |
6132460 | Thompson | Oct 2000 | A |
6149682 | Frid | Nov 2000 | A |
6152945 | Bachinski et al. | Nov 2000 | A |
6152957 | Jang | Nov 2000 | A |
6159238 | Killion et al. | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6183509 | Dibie | Feb 2001 | B1 |
6203568 | Lombardi et al. | Mar 2001 | B1 |
6210429 | Vardi et al. | Apr 2001 | B1 |
6221098 | Wilson et al. | Apr 2001 | B1 |
6254593 | Wilson | Jul 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6264682 | Wilson et al. | Jul 2001 | B1 |
6290673 | Shanley | Sep 2001 | B1 |
6325826 | Vardi | Dec 2001 | B1 |
6346089 | Dibie | Feb 2002 | B1 |
6358274 | Thompson | Mar 2002 | B1 |
6361555 | Wilson | Mar 2002 | B1 |
6565599 | Hong et al. | May 2003 | B1 |
6749628 | Callol et al. | Jun 2004 | B1 |
20010029397 | Thompson | Oct 2001 | A1 |
20010037137 | Vardi et al. | Nov 2001 | A1 |
20010039447 | Pinchasik et al. | Nov 2001 | A1 |
20010049548 | Vardi et al. | Dec 2001 | A1 |
20010056297 | Hojeibane | Dec 2001 | A1 |
20020055770 | Doran et al. | May 2002 | A1 |
20030036793 | Richter et al. | Feb 2003 | A1 |
20030097169 | Brucker et al. | May 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030139796 | Sequin et al. | Jul 2003 | A1 |
20030139803 | Sequin et al. | Jul 2003 | A1 |
20030167083 | Lashinski et al. | Sep 2003 | A1 |
20030195606 | Davidson et al. | Oct 2003 | A1 |
20030204244 | Stiger | Oct 2003 | A1 |
20040044400 | Cheng et al. | Mar 2004 | A1 |
20040176837 | Atladottir et al. | Sep 2004 | A1 |
Number | Date | Country |
---|---|---|
91 02 312 | Jun 1992 | DE |
0 461 791 | Dec 1991 | EP |
0 466 518 | Jan 1992 | EP |
0747 020 | Dec 1996 | EP |
0 804 907 | Nov 1997 | EP |
0 897 700 | Feb 1999 | EP |
0 904 745 | Mar 1999 | EP |
2673843 | Sep 1992 | FR |
2737969 | Feb 1997 | FR |
1217402 | Mar 1986 | SU |
1318235 | Jun 1987 | SU |
1389778 | Apr 1988 | SU |
1457921 | Feb 1989 | SU |
1482714 | May 1989 | SU |
WO 9516406 | Jun 1995 | WO |
WO 9521592 | Aug 1995 | WO |
WO 9623455 | Aug 1996 | WO |
WO 9624306 | Aug 1996 | WO |
WO 9624308 | Aug 1996 | WO |
WO 9634580 | Nov 1996 | WO |
WO 9707752 | Mar 1997 | WO |
WO 9715346 | May 1997 | WO |
WO 9716217 | May 1997 | WO |
WO 97418043 | Nov 1997 | WO |
WO 9745073 | Dec 1997 | WO |
WO 9819628 | May 1998 | WO |
WO 9836709 | Aug 1998 | WO |
WO 9904726 | Feb 1999 | WO |
WO 0007523 | Feb 2000 | WO |
WO 0121095 | Mar 2001 | WO |
WO 02068012 | Sep 2002 | WO |